Impact of Infections in Patients Receiving Pembrolizumab-Based Therapies for Non-Small Cell Lung Cancer.
Ethan A BurnsKelly GeeRyan B KieserJiaqiong XuYuqi ZhangAubrey CrenshawIbrahim N MuhsenCharisma MylavarapuAbdullah EsmailShivan ShahGodsfavour O UmoruKai SunCarlo GuerreroZimu GongKirk HeyneMonisha SinghJun ZhangEric H BernickerMaen AbdelrahimPublished in: Cancers (2022)
Infections occurred in nearly half of patients receiving pembrolizumab-based therapies for NSCLC. Infected patients had frequent hospitalizations, treatment delays, and poorer survival. ECOG status and anti-infective use at ICI initiation conferred a higher infection risk. Infection prevention and control strategies are needed to ameliorate the risk for infections in patients receiving ICIs.